The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to randomized phase 2 study results.The benefit appeared confined to individuals with HPV-negative disease, and a phase 3 trial to further evaluate the regimen in that population is planned.
Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.